Skip to Content
Developmental Therapeutics Program (DTP)
Last Updated: 04/02/15

TPB Publications

2001 Publications

  1. MacGregor, J.T., Collins, J.M., Sugiyama, Y., Tyson, C.A., Dean, J., Smith, L., Andersen, M., Curren, R.D., Houston, J.B., Kadlubar, F.F., Kedderis, G.L., Krishnan, K., Li, A.P., Parchment, R.E., Thummel, K., Tomaszewski, J.E., Ulrich, R., Vickers, A.E.M., and Wrighton, S.A., 2001. In Vitro Human Tissue Models in Risk Assessment: Report of a Consensus-Building Workshop. Toxicol. Sci. 59: 17-36.
  2. Snapka, R.M., Gao, H., Grabowski, D.R., Brill, D., Chan. K.K., Li, L., Li, G.C., and Ganapathi, R., 2001. Cytotoxic Mechanism of XK469: Resistance of Topoisomerase Ii Kockout Cells and Inhibition of Topoisomerase I . Biochem. Biophys. Res. Comm. 280: 1155-1160.
  3. Barchi Jr., J. J., D.A. Cooney, G.S. Ahluwalia, K. Gharehbaghi, J.M. Covey, I. Hochman, et al., 2001. Studies on the Mechanism of Action of 1-?-D-Arabinofuranosyl-5-azacytosine (fazarabine) in Mammalian Lymphoblasts. Journal of Exp. Therapeutics Oncol., 13, 191-203.
  4. Egorin, M.J., E.G Zuhowski, D.M. Rosen, D.L. Sentz, J.M. Covey, & J.L. Eiseman, 2001. Plasma Pharmacokinetics and Tissue Distribution of 17-(Allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 Mice. Cancer Chemother. Pharmacol., 47, 291-302.
  5. Ibrahim, S., Peggins, J., Knapton, A., Licht, T., & Aszalos, A. 2001. Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation. Anticancer research , 21 (2A), 847-56.
  6. Jia, L., Linnik, D.M., Jack, R.M. Yu, L 2001. Biostability and pharmacokinetics of LJP 920, an octameric Gal (alpha1-3) Gal conjugate for the inhibition of xenotransplantation rejection. J. Pharm. Pharmacol. 53: 999-1005.
  7. Jia, L. Pei, R. Lin, M. Young, X. 2001. Acute and subacute toxicity and efficacy of S-nitrosylated captopril, an ACE inhibitor possessing nitric oxide activities. Food Chem. Toxicol. 39: 1135-1143.
  8. Jia, L. Wong, H. 2001. In vitro and in vivo assessment of cellular permeability and pharmacodynamics of S-nitrosylated captopril, a nitric oxide donor. Br. J. Pharmacol. 134: 1697-1704.
  9. Koch, C. J., S.M. Hahn, K., Rockwell, J.M. Covey, W.G. McKenna, & S.M. Evans, 2001. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in Human Patients: Implications for Hypoxia Measurements in vivo by 2-Nitroimidazoles. Cancer Chemother. Pharmacol., 48, 177-187.
  10. Stecklair, K. P., D.R. Hamburger, M.J. Egorin, R.A. Parise, J.M. Covey, & J.L. Eiseman, 2001. Pharmacokinetics and Tissue Distribution of Halofuginone (NSC 713205) in CD2F1 Mice and Fischer 344 rats. Cancer Chemother. Pharmacol., 48, 375-382.
  11. Wong, H. Jia, L. Camden, J. Weitman, S. 2001. Liquid chromatography-mass spectrometry assay of a thiodiazole derivative in mice: application to pharmacokinetic studies. J. Chromatogr. 765: 55-62.

About the Branch Chief

For information regarding the TPB, please contact Dr. Jerry M. Collins, Associate Director, collinsje@mail.nih.gov